Research review
Do probiotics help with GI disease? What the research does and doesn't show
Some strains showed signals in trials for IBS and ulcerative colitis, but certainty was low to very low and nothing here is a treatment or a result for an unstrained product.
The evidence does not support probiotics as a treatment for irritable bowel syndrome, reflux, ulcers or diverticulitis. Trials found that some specific strains may ease some symptoms in some conditions, but certainty was low to very low in almost every analysis, and "probiotic" is not one thing. This page is research, not advice for a diagnosed condition.
What the evidence doesn't support
- A probiotic as a gut-disease treatment. No result below shows that, none is a result for a product that lists species without strains, and none shows probiotics replace medical care.
- "A probiotic" working for IBS in general. In 82 trials, only particular strains showed signals, and the reviewers' own certainty ratings were low or very low for nearly all of them.
- Anything for Crohn's disease. The 2024 inflammatory bowel disease review found no significant effect on remission or recurrence in Crohn's disease.
- A verified result for ulcers. We did not find a systematic review of probiotics alone for peptic ulcers that we could verify, so we report none.
What the trials found
Irritable bowel syndrome
A 2023 systematic review and meta-analysis of 82 placebo-controlled randomized trials in 10,332 adults with IBS found that only 24 trials were at low risk of bias. For global symptoms, certainty was moderate for Escherichia strains, low for Lactobacillus strains and L. plantarum 299V, and very low for combination probiotics. For abdominal pain it was low for Saccharomyces cerevisiae I-3856 and Bifidobacterium strains. For bloating or distension it was very low for combination probiotics and Bacillus strains. Adverse events were not significantly higher with probiotics. The authors concluded some strains or combinations may help but certainty was low to very low across almost all analyses. A separate network analysis of 81 trials (9,253 adults) ranked Lactobacillus acidophilus DDS-1 first for symptom severity and Bacillus coagulans MTCC 5856 among the leaders for pain and stool form, and said only some probiotics work for particular outcomes and the findings need confirming. Doses varied by trial.
Inflammatory bowel disease
A 2024 overview of 22 systematic reviews plus a meta-analysis of 45 randomized trials reported an odds ratio for clinical remission of 2.00 (95% CI 1.28 to 3.11) in ulcerative colitis and 1.61 (95% CI 0.21 to 12.50, not significant) in Crohn's disease. Probiotics did not produce better endoscopic results, did not lower recurrence in Crohn's disease, and adverse events were similar to control. Certainty was low, and multi-strain formulations appeared better in ulcerative colitis. These are results in people under medical care, not a reason to start a supplement.
Reflux (GERD)
A 2020 systematic review of 13 prospective studies (five high quality, two medium, six low) found 11 of 14 comparisons reported a benefit, but only five of those 11 concerned reflux symptoms such as regurgitation or heartburn; the rest were for dyspepsia, nausea, pain or gas. The authors, who worked for a probiotics manufacturer, said properly controlled, randomized, double-blind trials with enough participants are needed.
Diverticular disease
A 2025 meta-analysis of 13 studies (randomized trials and observational studies) in adults with diverticular disease found abdominal pain improved (SMD 0.63, 95% CI 0.38 to 0.88), bloating did not reach significance, and two trials showed fewer recurrences (relative risk 0.22). CRP fell in three studies of acute uncomplicated diverticulitis but could not be pooled. Certainty was low to very low.
Questions people ask
Can probiotics help IBS? Are they good for IBS, and which probiotics are good for IBS?
Some strains showed signals in trials, but certainty was low to very low, and the strains that showed a signal differ by symptom: Escherichia strains for global symptoms (moderate certainty), Saccharomyces cerevisiae I-3856 and Bifidobacterium for pain (low), and Bacillus coagulans MTCC 5856 for stool form in diarrhea-predominant IBS in the network analysis. Which strain suits which IBS subtype, including IBS-D, is not settled. This is research, not a recommendation; ask a doctor.
Are probiotics good for GERD or ulcers?
For reflux, a 2020 review reported benefits in some small, mixed-quality studies and called for better trials. For ulcers, we have no verified review to report. Persistent heartburn or stomach pain needs assessment.
Will probiotics help with diverticulitis?
A 2025 review found less abdominal pain and possibly fewer recurrences in people with diverticular disease, with low to very low certainty. Diverticulitis, an acute flare, is a medical matter: sudden severe pain, fever or vomiting needs urgent care, not a supplement.
Will probiotics help with chronic diarrhea?
We did not verify a review of probiotics for chronic diarrhea, so we report none. Diarrhea after antibiotics is covered in probiotics benefits. Chronic diarrhea needs a doctor to find the cause.
See also probiotics side effects and how to choose a good probiotic, and probiotics and inflammation.
When to talk to a doctor
A supplement is not a treatment for IBS, IBD, reflux, ulcers or diverticulitis. See a doctor for blood in stool, black stools, persistent pain, unexplained weight loss, trouble swallowing, vomiting or diarrhea that lasts. If you have a diagnosed gut condition, a weakened immune system, are pregnant or nursing, or take prescription medicine, ask a doctor or pharmacist before starting any probiotic.
Sources
- Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis A review of 82 trials in adults with IBS found some strains may help, but confidence in the evidence was low to very low almost everywhere.
- Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis A network analysis of 81 IBS trials found only some strains and mixtures beat placebo, and only for particular symptoms.
- Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta-analysis of randomized controlled trials A 2024 review found probiotic trials in ulcerative colitis reported more clinical remission, none in Crohn's disease, no better endoscopic results, and low certainty overall.
- Gastroesophageal Reflux Disease and Probiotics: A Systematic Review A 2020 review of 13 mostly small or lower-quality studies reported benefits for some reflux-related symptoms and said properly controlled trials are still needed.
- The Impact of Probiotics on Clinical Outcomes in Diverticular Disease: A Systematic Review and Meta-Analysis A 2025 review of 13 studies in diverticular disease found less abdominal pain and possibly fewer recurrences, with low to very low certainty.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.